BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23422147)

  • 1. Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS).
    Rivera-Hernandez T; Hartas J; Wu Y; Chuan YP; Lua LH; Good M; Batzloff MR; Middelberg AP
    Vaccine; 2013 Apr; 31(15):1950-5. PubMed ID: 23422147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modular virus-like particles for sublingual vaccination against group A streptococcus.
    Seth A; Kong IG; Lee SH; Yang JY; Lee YS; Kim Y; Wibowo N; Middelberg AP; Lua LH; Kweon MN
    Vaccine; 2016 Dec; 34(51):6472-6480. PubMed ID: 27866769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine.
    Chuan YP; Rivera-Hernandez T; Wibowo N; Connors NK; Wu Y; Hughes FK; Lua LH; Middelberg AP
    Biotechnol Bioeng; 2013 Sep; 110(9):2343-51. PubMed ID: 23532896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
    Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
    Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
    Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
    Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-Activation of Th17 and Antibody Responses Provides Efficient Protection against Mucosal Infection by Group A Streptococcus.
    Chen X; Li N; Bi S; Wang X; Wang B
    PLoS One; 2016; 11(12):e0168861. PubMed ID: 28030629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.
    Nevagi RJ; Khalil ZG; Hussein WM; Powell J; Batzloff MR; Capon RJ; Good MF; Skwarczynski M; Toth I
    Acta Biomater; 2018 Oct; 80():278-287. PubMed ID: 30266637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines.
    Middelberg AP; Rivera-Hernandez T; Wibowo N; Lua LH; Fan Y; Magor G; Chang C; Chuan YP; Good MF; Batzloff MR
    Vaccine; 2011 Sep; 29(41):7154-62. PubMed ID: 21651936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
    J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
    Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
    J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.
    Mortensen R; Christensen D; Hansen LB; Christensen JP; Andersen P; Dietrich J
    PLoS One; 2017; 12(4):e0175707. PubMed ID: 28414746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus.
    Batzloff MR; Yan H; Davies MR; Hartas J; Lowell GH; White G; Burt DS; Leanderson T; Good MF
    J Infect Dis; 2005 Oct; 192(8):1450-5. PubMed ID: 16170764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
    Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.
    Hunter Z; Smyth HD; Durfee P; Chackerian B
    Vaccine; 2009 Dec; 28(2):403-14. PubMed ID: 19849995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.
    Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B
    mBio; 2019 Nov; 10(6):. PubMed ID: 31772056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine.
    Jackson EM; Herbst-Kralovetz MM
    PLoS One; 2012; 7(7):e41529. PubMed ID: 22855691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.
    Tamminen K; Malm M; Vesikari T; Blazevic V
    Viral Immunol; 2016 Jun; 29(5):315-9. PubMed ID: 27135874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus.
    Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Med Chem; 2016; 13(1):22-27. PubMed ID: 27449794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.